Targit trial – Targeted Intraoperative Radiotherapy for Breast Cancer
The TARGIT-A trial is
-for patients who are 45 years or older and is designed to test if a risk adjusted approach using a single dose of IORT using TARGIT gives similar results as the usual radiotherapy over several weeks.
This trial has completed recruitment. The first results of the TARGIT-A trial were presented in ASCO 2010 and published in the Lancet in July 2010. The updated results after trial closure (n=3451) were presented in San Antonio Breast Cancer Symposium on 6 December 2012.
The TARGIT-B trial is
for patients who are younger than 45 years, or have a higher risk of cancer recurrence and is designed to test if giving an intraoperative tumour bed boost using TARGIT is superior to the usual externally given tumour bed boost, both in addition to whole breast radiotherapy. This trial starts recruitment in Spring 2013
Both these trials are for patients who have a breast conserving surgery i.e., wide local excision, or lumpectomy. Breast cancer patients who need a mastectomy are not currently suitable for TARGIT.
Recent presentations about TARGIT at international scientific meetings and conference
March 2013 St Gallen Breast Cancer Conference: Two new posters:
6 December 2012 (General session 4)
Late breaking plenary presentation at the 2012 San Antonio Breast Cancer Symposium: TARGIT-A trial: Updated results and first analysis of survival
Click on Thursday, 6 December - then General session 4 - 2nd presentation
Intraoperative radiotherapy vs. External beam radiotherapy - ASCO Post (15 Feb 2013)
If you cannot access this on the original site the single page can be downloaded here TARGIT-A trial - risk adapted IORT vs EBRT
19 March 2011
At the 12th International St.Gallen Breast Cancer Conference, St.Gallen, Switzerland, the consensus panel of 52 experts at the Consensus session on the last day of the conference voted in favour of using intraoperative radiotherapy.
The TARGIT - A trial
In the randomised TARGIT-A trial, two policies of local radiation treatment after breast cancer surgery are compared:
Breast cancer patient (>=45 years) suitable for breast conserving surgery
The TARGIT technique uses the Intrabeam device for delivering precise and timely dose of intraoperative radiotherapy accurately to the tumour bed. This device was developed by an collaborative effort between University College London and the industry. It has had extensive experience since its first use on 2 July 1998.
Visit: The TARGIT trial Blog
This page lists the original articles about the TARGIT treatment, the Targit trial, and evolution of the Targit approach.
Targeted intraoperative radiotherapy Literature
[NOTE: these papers can be downloaded strictly for personal use only. This site is maintained by Dr Jayant S Vaidya ]
Pathological and biological rationale of
partial breast irradiation (PBI) and the basis of the Targit Trial
Could MRI be useful to select patients for breast conserving surgery?
The Core trial Protocol of the Targit Trial
The UK Pilot Study of intraoperative radiation therapy:
the first full paper about Targit
The surgical technique of targeted intraoperative radiotherapy
(TARGIT) for early breast cancer treatment
as used in the Targit trial
A possible one-stop out patient treatment for small breast cancers
PhD Thesis of Jayant S Vaidya
2003 San Antonio Breast Cancer Symposium
30-minute invited presentation about the Targit trial
Poster discussion about cosmetic results of
the (Targit) intraoperative radiation therapy boost cases
Acute and Late Toxicity data about the Targit approach.
Reviews, Editorial, Viewpoint
Radiobiology of Targeted intraoperation radiation therapy (TARGIT)
Mathematical Modelling of breast cancer growth, recurrence
and intra-operative radiotherapy (IORT)
Targit under Local Anaesthetic
Targit boost :- resuts in a very low recurrence
5-yr actuarial = 1.52%
Novel effects of TARGIT on tumour micro-environment
Patient Information about Targit as a Single Procedure
Patient Information about Targit as a Subsequent Procedure
TARGIT is an elegant approach of partial breast irradiation (PBI) for breast cancer. Please scroll down for the literature about the TARGIT approach and the TARGIT trial